Transcranial Direct Current Stimulation (tDCS) for Treatment-Resistant Obsessive-Compulsive Disorder (FRONT)

Obsessive-Compulsive Disorder Clinical Trial

— FRONT  

Official title:

Randomized, Sham-Controlled Trial of Transcranial Direct Current Stimulation (tDCS) for Treatment-Resistant Obsessive-Compulsive Disorder (FRONT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02743715
• Other study ID #: FRONT2016
• Status: Completed
• Phase: N/A
• Start date: April 2016
• Est. completion date: August 2018

Study information

• Verified date: December 2020
• Source: University of Sao Paulo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Neuromodulation techniques for the treatment of Obsessive-Compulsive Disorder (OCD) have expanded with the greater understanding of the brain circuits involved in this disorder. Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation technique that has been studied as an alternative for strategy for treatment-resistant OCD. The main study is a randomized, sham-controlled, double-blinded trial tDCS for OCD patients unresponsive to cognitive-behavioral therapy and/or selective serotonin reuptake inhibitors. Forty-four patients will be randomized to two groups: active or simulated intervention. The intervention consisted of delivering an electric current of 2mA to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, and the anode positioned in the deltoid (neutral region), during 30-minutes, for four consecutive weeks. The primary outcome was the reduction in baseline YBOCS scores before and after of tDCS treatment. Secondary outcomes include measures of depressive and anxiety symptoms, genetic markers, motor cortical excitability and performance in neurocognitive tests.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: August 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients diagnosed with OCD according to DSM IV criteria
• YBOCS score of 16 and above or =10 (for the presence of only compulsions or only obsessions)
• Patients with other psychiatric comorbidities are not excluded, however, OCD should be the most important disease .
• Age between 18 and 65
• Patients who failed one or more treatments
• Patients with no previous treatment for OCD will be treated with one first line treatment before being considered to participate in the tDCS trial.
• Voluntary and competent to consent

Exclusion Criteria:

• Other diagnostic axis I whose treatment take precedence over the treatment of OCD (bipolar affective disorder; dependence alcohol; schizophrenia or psychotic disorders; dementia)
• Presence of other neurological diseases or severe clinical as neurodegenerative diseases, severe aphasia, malignancies activity, epilepsy, previous head injury, congestive heart failure or chronic obstructive pulmonary disease stage III or IV;
• Presence of severe suicidal ideation (Structured planning suicide or attempted suicide in the past 4 weeks);
• Pregnancy;
• Inability to provide informed consent;
• Specific contraindication to tDCS: ( metal plates on the head, anatomic changes.);
• In relation to the current use of psychotropic drugs will be permitted, provided they are in doses stable for at least 6 weeks.

Related Conditions & MeSH terms

• Disease
• Obsessive-Compulsive Disorder

Intervention

Device:
• Active tDCS (transcranial direct current stimulation)
An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
• Sham tDCS
The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.

Locations

Country	Name	City	State
Brazil	USP	São Paulo

Sponsors (2)

Lead Sponsor	Collaborator
University of Sao Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in baseline Yale-Brown Obsessive Compulsive Scale score		weeks 4,6,9,12
Secondary	Beck Depression Inventory symptoms,		baseline, weeks 6 and 12
Secondary	Beck Anxiety Inventory		baseline, week 6 and 12
Secondary	Global Clinical Impression Scale - improvement		baseline, week 6 and 12